Transforming Blood Cancer Detection Through European Innovation

The SANGUINE Project Showcase Event:

Advancing the HemaChip from Research to Impact

Every year, around 300,000 people across the EU are diagnosed with a haematological malignancy, including leukaemia, lymphoma and multiple myeloma.

 

Yet diagnosing blood cancer remains a complex challenge. With more than 100 different types and subtypes, many diseases share overlapping clinical and laboratory features, requiring multiple tests to reach an accurate diagnosis.

 

As part of the EU Cancer Mission, the SANGUINE project has set out to change this. Over the past four years, this EU-funded initiative has worked to tackle this issue and revolutionise blood cancer detection. Its flagship innovation, the HemaChip, can screen for multiple blood cancers simultaneously through a fast, minimally invasive and cost-effective test.

 

Join us in Brussels on 13–14 October to highlight the groundbreaking achievements of the SANGUINE project, explore the science behind the HemaChip, share lessons learned, and discuss next steps for scaling up this promising innovation to benefit patients across Europe and beyond. Registrations are now open.

13 October 2026 14:00 - 20:00 CEST 14 October 2026 9:00 - 15:00 CEST

The Hoxton
Square Victoria Régina 1, 1210 Brussels, Belgium

Registrations open 16 9

Breakthroughs in cancer research and biomedical technology have transformed the detection and treatment of blood cancers, saving thousands of lives every year.

The HemaChip represents another major step forward. By eliminating the need for sequencing, it significantly reduces the cost of testing while supporting faster diagnosis, improved patient outcomes, and more effective population-based screening programmes.

Now it’s time to give the HemaChip the attention it deserves.

This upcoming showcase event will bring together medical professionals, researchers, patient representatives, industry leaders and policymakers to explore how innovative diagnostics can be implemented at scale, how Europe can remain a global leader in cancer research, and why continued investment in health innovation is essential for both citizens and Europe’s competitiveness agenda.

Discussions will include:

  • The latest advances in haematology and blood cancer diagnostics
  • Demonstrations of the science behind the HemaChip
  • Pathways for implementing the technology within European health systems
  • Lessons learned and best practices from the SANGUINE project
  • The future of EU investment in cancer research as a strategic driver of health, innovation and European competitiveness

Whether you are involved in research, healthcare, policy or innovation, this event offers an opportunity to exchange knowledge, build collaborations and help shape the future of blood cancer diagnostics in Europe. 

EN FundedbytheEU RGB POSThis project has received funding from the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement Nº 101097026.

Related Resources

  • SANGUINE official website
    visit